ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifying holding for the purposes of the Venture Capital Trust rules (“VCT Advance Assurance”) and a qualifying company for the purposes of the Enterprise Investment…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed. Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: “We are…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company“), the specialist drug discovery and development company, is pleased to announce the successful completion of the conditional fund raise, comprising the Placing and Subscription, announced earlier today. The Company has conditionally raised, in aggregate, £8.3 million (before expenses) by way of the placing of 14,901,800 new ordinary shares…

Proposed fundraising to finance the pivotal Phase III trial for the Company’s lead product, Lupuzor™ Friday, February 5, 2016 – 10:46 ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce a proposed conditional fund raise of not less than £7.5 million. This includes a proposed conditional…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a summary of the Investigators Meeting which was held in Paris on 11th/12th  December. The key objective of the event was to bring together key specialists in the field of Lupus who will be actively involved as…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The Company is pleased to confirm that…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide an update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The pivotal Phase III trial is progressing in…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that Ajay Agrawal has stepped down as Non-Executive Director with immediate effect. Tim McCarthy, Non-Executive Chairman said: “We would like to thank Ajay for his contribution whilst at ImmuPharma.  “In the short period of time as Chairman, I have become…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect. Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2015 (the “Period”). Although we are pleased to report our interim results, we are saddened by the passing of our Chairman, Richard Warr, in late July.  …

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is truly saddened to announce that Richard Warr, Chairman, passed away late last week. Dimitri Dimitrou, Chief Executive Director said: “No words can truly convey the deep sadness we feel at Richard’s untimely passing away. Richard will be remembered and missed…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health – ClincialTrials.gov website has now gone ‘live’ confirming Lupuzor’s™ pivotal Phase III trial protocol and the current clinical commencement and completion of the study. Further details can be…

ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of US$2,000,000 plus additional capital of up to US$12,000,000, at the Company’s discretion, subject to certain criteria, over a two year period. Further disclosure…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that Dr Sylviane Muller the key inventor of Lupuzor™ and Research Director at Centre National de la Recherche Scientifique (“CNRS”), and has received “The CNRS Medal of Innovation”  for her discoveries made on the mechanism of action…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table attached, click here. Please also refer to the ‘Notice of the 2015 Annual General Meeting’ in…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2014 will be posted to shareholders today. The Annual Report will be available later today, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2014. Key Highlights: LupuzorTM Agreement signed with Simbec-Orion, an international clinical research organisation, to undertake crucial Phase III clinical trial including a commitment to reinvest a significant…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Dr Stéphane Méry as non-executive director. Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides an update on its lead Cancer programme – IPP-204106. As previously stated, the Phase I/IIa clinical trial with the next generation “polyplexed Nucant” formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been…